Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology (KURA – Research Report) and keeping the price target at $24.00.
Charles Zhu has given his Buy rating due to a combination of factors including Kura Oncology’s recent updates on their clinical trials and financial health. The company has shown promising results in their KOMET-001 trial, achieving its primary endpoint with an overall response rate between 21-29%, which is a positive indicator for their monotherapy treatment in relapsed/refractory NPM1-mutated AML. Additionally, Kura has submitted a New Drug Application for this treatment, with expectations for a Priority Review decision soon, which could accelerate its path to market.
Furthermore, Kura’s financial position is strong, with over $703 million in cash and equivalents, providing an operational runway into 2027. This financial stability, coupled with potential additional milestones, positions the company well for future developments. The management’s focus on expanding their FTI pipeline and exploring combination therapies also suggests potential for growth and innovation, making Kura Oncology an attractive investment opportunity.
Zhu covers the Healthcare sector, focusing on stocks such as Kura Oncology, Merus, and Protara Therapeutics. According to TipRanks, Zhu has an average return of -14.0% and a 29.47% success rate on recommended stocks.